

Minutes of the REC meeting held on 10-1-2023

The Research Ethics Committee (REC) zoom meeting was held on January 10, 2023. The following members of REC attended the meeting:

1. Prof. Dr. Saima Pervaiz Iqbal	Chairperson
2. Prof. Dr. Munir Saleemi	Member
3. Prof. Dr. Jamshed Akhtar	Member
4. Dr. Farkhanda Ghafoor	Member
5. Prof. Dr. Nazli Hossain	Member
6. Dr. Sualeha Siddiqui Sheikhani	Member
7. Prof. Marie Andraes	Member
8. Prof. Dr. Amjad Mehboob	Member
9. Dr. Nighat Murad	Focal Person NBC
10. Mr. Khalid Mehmood	Assistant (NBC-Secretariat)
11. Mr. Waryal Ali Daheri	L.D.C (NBC-Secretariat)

The following projects reviewed / discussed:

NBC-889:

Title: **A QUALITATIVE ASSESSMENT OF THE IMPACT OF LAW ON ACCESS TO SAFE ABORTION SERVICES FOR WOMEN IN SINDH, PAKISTAN.**

Principal Investigator: Dr. Sheena Hadi, Aahung D-78, Khayaban-e-Saadi, Block -2, Clifton, Karachi.

Final REC Comments:

1. Please provide more clarity as to the stakeholders being interviewed and how they will be approached.
2. The protocol needs to be revisited within our local context. Abortions are used as a means of emergency contraception/family planning services in our country so it needs to be tailored accordingly.
3. It seems that the project is more focused on the perception of our Laws rather than the laws itself which is fine but needs clarity in the protocol.

NBC-893:

Title: **ENGAGING PRIVATE PROVIDERS FOR IMMUNIZATION-INTEGRATED SERVICES IN HIGH-RISK UCS OF KARACHI.**

Principal Investigator: Dr. Shehla Zaidi
Ground floor – faculty offices, Ibn Ridwan Building, Aga Khan University, Stadium Road, Karachi.

Final REC Comments:

Project Approved

NBC-916:

Title: **HOW CAN TECHNOLOGY SOLUTIONS SUPPORT PAKISTANI WOMEN TO OVERCOME BARRIERS TO ENTREPRENEURSHIP?.**

Principal Investigator: Elor Nkereuwem
Johns Hopkins University School of Advanced International Studies
1740 Massachusetts Ave., N.W., Washington, DC 20036,
United States of America

Final REC Comments:

1. We are not sure as to who is the PI of said study? What is the role of Javeria Rana?
2. How will Pakistan or Pakistani society benefit from the results of this study?

COVID-132:

Title: **A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE II/III STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF JT001 (VV116) FOR THE EARLY TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN PARTICIPANTS WITH MILD TO MODERATE COVID-19.**

Principal Investigator: Dr. Ume Sughra (Country PI)
Al-Shifa Research Centre- Al-Shifa Trust Eye Hospital, Jhelum Road,
Rawalpindi


Final REC Comments:

1. The country specific documents are not found.
2. The study participants will not be paid for this trial as mentioned in ICF. Any specific reason for this strategy?
3. MTA, DSMB, Insurance related issues are not found.
4. Will study participants shall be shared with the results?
5. Who shall pay for expenses if during course of illness patient develops severe disease and requires hospital admission?
6. Types of blood tests that shall be performed must be mentioned in ICF.
7. Details how specimens shall be discarded and future use should be clearly mentioned.
8. How many subjects shall be enrolled from each trial site?
9. Are all trial sites having updated DRAP approval?
10. Are all co PI involved previously in such research projects?
11. Are vaccinated individuals being enrolled in the study?
12. Is this study looking at the new variants now emerging in China?
13. What will happen of patient's transition to moderate or severe disease?

Next meeting:

The next zoom meeting will be held at 03:00 pm on January 17, 2023. The following projects will be reviewed:

1. NBC-900
2. NBC-896
3. COVID-133



Focal Person NBC




Chairperson REC

Next meeting:

The next zoom meeting will be held at 03:00 pm on February 14, 2023. The following projects will be reviewed:

1. NBC-912
2. NBC-913
3. NBC-914
4. COVID-135



Focal person NBC



Chairperson REC